Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Specific Targeting of Mast cells via ST-2 receptor for Intervention in Ocular Diseases
Author Affiliations & Notes
  • Vinay Kumar Pulimamidi
    Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Rahul Kumar Verma
    Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Nishant R. Sinha
    Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Lei Xi
    Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Olufemi Samuel Folorunso
    Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Sunil Chauhan
    Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Vinay Pulimamidi None; Rahul Verma None; Nishant Sinha None; Lei Xi None; Olufemi Folorunso None; Sunil Chauhan None
  • Footnotes
    Support  NEI R01EY029727
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3603. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vinay Kumar Pulimamidi, Rahul Kumar Verma, Nishant R. Sinha, Lei Xi, Olufemi Samuel Folorunso, Sunil Chauhan; Specific Targeting of Mast cells via ST-2 receptor for Intervention in Ocular Diseases. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3603.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mast cells play a crucial role in inflammation by releasing inflammatory mediators, which promote angiogenesis and immune cell recruitment in ocular injury. To primarily target mast cells for interventions in ocular diseases, we exploited ST-2 a cell surface receptor predominantly expressed by mast cells. In this study, we investigated the selective targeting of mast cells using a drug-loaded liposomal delivery via the ligand of ST-2 receptor.

Methods : We designed a cycloheximide loaded liposomal system which was decorated with ST2 specific ligand to selectively target mast cells. Liposomes were prepared using lipid composition composed of 48:50:2 molar ratio of phosphatidylcholine (PC), cholesterol, and Maleimide polyethylene glycol-di-stearoyl phosphor-ethanolamine (Mal-PEG-DSPE) by thin-film hydration and sonication method. Lipid thin layer was rehydrated with cycloheximide solution in PBS with vertexing, followed by sonication. ST-2 ligand (interleukine-33) was decorated on liposomes using NHS-Mal cross-linking chemistry. The physicochemical characteristics of these liposomes, including their shape, size, drug encapsulation efficiency, and drug release, were evaluated by TEM, Dynamic light scattering (DLS), and dialysis-bag method respectively. Further, we examined the effect of drug-loaded IL33-liposomes on the inflammatory response in human mast cells (LUVA), assessing the expression of pro-inflammatory cytokines through qRT-PCR.

Results : The drug loaded IL33-liposomes were spherical in shape with particles size of 101.7±18.3 nm with a surface charge of 1.92±0.8 mV. The conjugated liposomes showed significantly higher cellular uptake in human mast cells compared to normal liposomes without ligand. ST2-mediated activation of matured mast cells triggered a proinflammatory response, characterized by an enhanced production of proinflammatory TNF-α (p<00.5) and Interleukin-1β (p<0.05)), which was significantly decreased after treatment with cycloheximide loaded liposomes in 18 h. Further, drug loaded ST2-ligand decorated liposomes induced significant apoptosis in mast cells.

Conclusions : Our data demonstrate that ST2-ligand decorated liposomes target mast cells and inhibit their inflammatory function, suggesting a potential therapeutic approach for mast cell related diseases.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×